Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020

Rhea-AI Summary

On July 30, 2020, Neurocrine Biosciences (Nasdaq: NBIX) announced its participation in the William Blair Biotech Focus Conference 2020, scheduled for August 6, 2020, at 12:00 p.m. ET. Kyle Gano, Chief Business Development and Strategy Officer, will lead a panel on "New Therapies Impacting the Epilepsy Treatment Landscape." The event will be webcasted live, with a replay available on the company's website within an hour post-event. Neurocrine Biosciences specializes in developing treatments for neurological and psychiatric disorders, with a strong portfolio of FDA-approved therapies.

News Market Reaction – NBIX

-1.12%

-1.12% Session move

In the trading session that priced this news, NBIX declined 1.12%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, July 30, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the William Blair Biotech Focus Conference 2020 at 12:00 p.m. ET on Thursday, August 6, 2020. Kyle Gano, Chief Business Development and Strategy Officer, will participate in a panel session titled "New Therapies Impacting the Epilepsy Treatment Landscape" at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical development programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-the-william-blair-biotech-focus-conference-2020-301103412.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When is Neurocrine Biosciences participating in the William Blair Biotech Focus Conference 2020?

Neurocrine Biosciences will participate in the William Blair Biotech Focus Conference 2020 on August 6, 2020, at 12:00 p.m. ET.

Who will represent Neurocrine Biosciences at the conference?

Kyle Gano, Chief Business Development and Strategy Officer, will represent Neurocrine Biosciences at the conference.

What is the topic of the panel session Neurocrine Biosciences is participating in?

The panel session is titled "New Therapies Impacting the Epilepsy Treatment Landscape."

How can I watch the Neurocrine Biosciences conference presentation?

The live presentation can be accessed via webcast on Neurocrine Biosciences' website under the Investors section.

Will there be a recording of Neurocrine Biosciences' presentation available?

Yes, a replay of the presentation will be available on the website approximately one hour after the event and archived for about one month.